KLRK1 and cancer: Due to their enhanced expression in almost all cancer types, NKG2DL are regarded as universal targets for adoptive immunotherapy with effector lymphocytes endogenously expressing NKG2D or engineered with an NKG2D-based chimeric antigen receptor [7,8].